Advanced Search

Show simple item record

dc.contributor.authorUlusoy, Nafia Gökçe
dc.contributor.authorEmirdağ, Safiye
dc.contributor.authorSözer, Ece
dc.contributor.authorRadwan, Mohamed O.
dc.contributor.authorÇiftçi, Halil İbrahim
dc.contributor.authorAksel, Mehran
dc.contributor.authorŞahin Bölükbaşı, Serap
dc.contributor.authorÖzmen, Ali
dc.contributor.authorYaylı, Nurettin
dc.contributor.authorKarayıldırım, Tamer
dc.contributor.authorAlankuş, Özgen
dc.contributor.authorTateishi, Hiroshi
dc.contributor.authorOtsuka, Masami
dc.contributor.authorFujita, Mikako
dc.contributor.authorSever, Belgin
dc.identifier.citationUlusoy, N. G., Emirdağ, S., Sözer, E., Radwan, M. O., Çiftçi, H., Aksel, M., ... & Sever, B. (2022). Design, semi-synthesis and examination of new gypsogenin derivatives against leukemia via Abl tyrosine kinase inhibition and apoptosis induction. International Journal of Biological Macromolecules.en_US
dc.description.abstractChronic myelogenous leukemia (CML) is characterized by Philadelphia translocation arising from Bcr-Abl fusion gene, which encodes abnormal oncoprotein showing tyrosine kinase (TK) function. Certain mutations in kinase domain, off-target effects and resistance problems of current TK inhibitors require the discovery of novel Abl TK inhibitors. For this purpose, herein, we synthesized new gypsogenin derivatives (6a-l) and evaluated their anticancer effects towards CML cells along with healthy cell line and different leukemic cells. Among these compounds, compound 6l was found as the most active anti-leukemic agent against K562 CML cells compared to imatinib exerting less cytotoxicity towards PBMCs (healthy). This compound also revealed significant anti-leukemic effects against Jurkat cell line. Besides, compound 6l enhanced apoptosis in CML cells with 52.4 % when compared with imatinib (61.8 %) and inhibited Abl TK significantly with an IC50 value of 13.04 ± 2.48 μM in a large panel of kinases accentuating Abl TK-mediated apoptosis of compound 6l in CML cells. Molecular docking outcomes showed that compound 6l formed mainly crucial interactions in the ATP-binding cleft of Abl TK similar to that of imatinib. Ultimately, in silico pharmacokinetic evaluation of compound 6l indicated that this compound was endowed with anti-leukemic drug candidate features.en_US
dc.subjectAbl tyrosine kinaseen_US
dc.subjectChronic myelogenous leukemiaen_US
dc.subjectGypsogenin derivativesen_US
dc.subjectMolecular dockingen_US
dc.titleDesign, semi-synthesis and examination of new gypsogenin derivatives against leukemia via Abl tyrosine kinase inhibition and apoptosis inductionen_US
dc.departmentAFSÜ, Eczacılık Fakültesi, Temel Eczacılık Bilimleri Bölümüen_US
dc.contributor.institutionauthorŞahin Bölükbaşı, Serap
dc.relation.journalInternational Journal of Biological Macromoleculesen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US

Files in this item


This item appears in the following Collection(s)

Show simple item record